tetano
Editor, Senior Moderator
Aging Health Res
. 2023 Jun;3(2):100130.
doi: 10.1016/j.ahr.2023.100130. Epub 2023 Mar 5.
Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years
Kohei Fujita[SUP] 1 2 [/SUP], Osamu Kanai[SUP] 1 2 [/SUP], Hiroaki Hata[SUP] 1 3 [/SUP], Kenjiro Ishigami[SUP] 1 4 [/SUP], Kazutaka Nanba[SUP] 1 5 [/SUP], Naoki Esaka[SUP] 1 6 [/SUP], Koichi Seta[SUP] 1 7 [/SUP], Tadashi Mio[SUP] 2 8 [/SUP], Takao Odagaki[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Molnupiravir is being widely used as a treatment for coronavirus disease 2019 (COVID-19); however, its acceptability and safety in older patients aged ≥ 80 years in real-world clinical practice is not well understood.
Methods: We conducted a single-centre retrospective study and assessed the outcome of patients with COVID-19 treated with molnupiravir according to the following criteria: (A) discontinuation rate of molnupiravir; (B) type, frequency, and severity of adverse events; (C) all-cause mortality within 30 days of the diagnosis of COVID-19.
Results: Forty-seven patients (46.1%) were aged ≥ 80 years (older patients) and 55 (53.9%) were aged < 80 years (younger patients). There were no significant differences in coexisting diseases and history of vaccination for COVID-19 between older and younger patients. Older patients were significantly more likely to have moderate disease (moderate 1 and 2) according to the Japanese Ministry of Health, Labour and Welfare classification than younger patients. During treatment, 8.5% of older patients and 1.8% of younger patients stopped taking molnupiravir, but the difference was not significant. Adverse events were observed in 39/102 (38.2%) patients. The most common adverse events were diarrhoea (9.8%), exacerbation of coexisting diseases (6.9%), bone marrow suppression (6.9%), liver dysfunction (5.9%), and loss of appetite (4.9%). Most adverse events were minor, ranging from grades 1 to 3. The all-cause mortality rate was 10.8%, and no molnupiravir-related deaths were observed.
Conclusions: Molnupiravir treatment is acceptable and safe in older patients with COVID-19 aged ≥ 80 years.
Keywords: Anti-viral agent; Covid-19; Molnupiravir; Older patients; Pandemic; SARS-CoV-2.
. 2023 Jun;3(2):100130.
doi: 10.1016/j.ahr.2023.100130. Epub 2023 Mar 5.
Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years
Kohei Fujita[SUP] 1 2 [/SUP], Osamu Kanai[SUP] 1 2 [/SUP], Hiroaki Hata[SUP] 1 3 [/SUP], Kenjiro Ishigami[SUP] 1 4 [/SUP], Kazutaka Nanba[SUP] 1 5 [/SUP], Naoki Esaka[SUP] 1 6 [/SUP], Koichi Seta[SUP] 1 7 [/SUP], Tadashi Mio[SUP] 2 8 [/SUP], Takao Odagaki[SUP] 1 [/SUP]
Affiliations
- PMID: 36919008
- PMCID: PMC9985534
- DOI: 10.1016/j.ahr.2023.100130
Abstract
Background: Molnupiravir is being widely used as a treatment for coronavirus disease 2019 (COVID-19); however, its acceptability and safety in older patients aged ≥ 80 years in real-world clinical practice is not well understood.
Methods: We conducted a single-centre retrospective study and assessed the outcome of patients with COVID-19 treated with molnupiravir according to the following criteria: (A) discontinuation rate of molnupiravir; (B) type, frequency, and severity of adverse events; (C) all-cause mortality within 30 days of the diagnosis of COVID-19.
Results: Forty-seven patients (46.1%) were aged ≥ 80 years (older patients) and 55 (53.9%) were aged < 80 years (younger patients). There were no significant differences in coexisting diseases and history of vaccination for COVID-19 between older and younger patients. Older patients were significantly more likely to have moderate disease (moderate 1 and 2) according to the Japanese Ministry of Health, Labour and Welfare classification than younger patients. During treatment, 8.5% of older patients and 1.8% of younger patients stopped taking molnupiravir, but the difference was not significant. Adverse events were observed in 39/102 (38.2%) patients. The most common adverse events were diarrhoea (9.8%), exacerbation of coexisting diseases (6.9%), bone marrow suppression (6.9%), liver dysfunction (5.9%), and loss of appetite (4.9%). Most adverse events were minor, ranging from grades 1 to 3. The all-cause mortality rate was 10.8%, and no molnupiravir-related deaths were observed.
Conclusions: Molnupiravir treatment is acceptable and safe in older patients with COVID-19 aged ≥ 80 years.
Keywords: Anti-viral agent; Covid-19; Molnupiravir; Older patients; Pandemic; SARS-CoV-2.